Home > Insider Trading > Filing (0001104659-16-163806)

Filing Details

Accession Number:: 0001104659-16-163806
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2016-12-23 18:03:40
Reporting Period:: 2016-10-24

Filing Date:: 2016-12-23
Accepted Time:: 2016-12-23 18:03:40
Original Submission Date:: 2016-10-26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1456590	Versant Venture Capital Iv, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456591	Versant Side Fund Iv, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589095	Versant Affiliates Fund V, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589097	Versant Venture Capital V, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589098	Versant Ophthalmic Affiliates I, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1612235	Versant Venture Capital V (Canada), Lp	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-10-24	437,247	$0.00	676,895	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	3,100,477	$0.00	3,777,372	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	231,077	$0.00	4,008,449	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	95,596	$14.00	4,104,045	No	4	P	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	2,754	$0.00	2,754	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	19,524	$0.00	22,278	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	1,454	$0.00	23,732	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	602	$14.00	24,334	No	4	P	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	2,210,417	$0.00	2,210,417	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	173,167	$0.00	2,383,584	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	60,219	$14.00	2,443,803	No	4	P	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	66,490	$0.00	66,490	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	5,210	$0.00	71,700	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	168,224	$0.00	168,224	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	13,180	$0.00	181,404	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	4,583	$14.00	185,987	No	4	P	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	73,704	$0.00	73,704	No	4	C	Indirect	Footnote
Common Stock	Acquisiton	2016-10-24	5,774	$0.00	79,478	No	4	C	Indirect	Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	P	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	P	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	P	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	P	Indirect	Footnote
No	4	C	Indirect	Footnote
No	4	C	Indirect	Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Shares	Disposition	2016-10-24	437,247	$0.00	437,247	$0.00
Common Stock	Series A-1 Preferred Shares	Disposition	2016-10-24	2,754	$0.00	2,754	$0.00
Common Stock	Series A-2 Preferred Shares	Disposition	2016-10-24	3,100,477	$0.00	3,100,477	$0.00
Common Stock	Series A-2 Preferred Shares	Disposition	2016-10-24	19,524	$0.00	19,524	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	2,210,417	$0.00	2,210,417	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	66,490	$0.00	66,490	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	168,224	$0.00	168,224	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	73,704	$0.00	73,704	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	231,077	$0.00	231,077	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	1,454	$0.00	1,454	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	173,167	$0.00	173,167	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	5,210	$0.00	5,210	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	13,180	$0.00	13,180	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	5,774	$0.00	5,774	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016.
These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein.
These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein.
These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein.
These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein.
These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.
These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein.